Preprint
Review

This version is not peer-reviewed.

Does Metabolic Bariatric Surgery Prevent Cancer? A Bradford Hill Appraisal for the Surgical Oncologist

  † Joint First Authorship: These Authors Contributed Equally to this Work.

Submitted:

17 November 2026

Posted:

18 November 2026

You are already at the latest version

Abstract
Excess adiposity causes at least 13 cancers, and metabolic bariatric surgery (MBS) is increasingly presented as cancer-preventive. We appraised the evidence linking obesity, intentional weight loss and cancer against the Bradford Hill viewpoints, integrating literature published up to October 2026, including the IFSO GRADE-based position statement and a Nordic cohort of 784,105 adults. The obesity–cancer association fulfils the criteria of strength, consistency, biological gradient, temporality and plausibility. After MBS, matched cohorts and meta-analyses consistently report a 20–35% lower incidence of obesity-associated cancers, most clearly for endometrial, ovarian and liver cancer, and the Nordic cohort confirmed a 19% reduction irrespective of age or sex. However, no randomised trial has measured cancer incidence after MBS, certainty is low to very low, and oesophageal, gastric, pancreatic and prostate cancers show neutral or unfavourable signals. Incretin therapy appears protective in observational data but neutral in randomised trials. For surgical oncologists, altered anatomy delays the diagnosis of upper gastrointestinal cancer and changes reconstructive options. The protective association is real, coherent and site-specific but not yet proven causal; it should be discussed as an additional benefit in eligible patients, never as a stand-alone indication.
Keywords: 
;  ;  ;  ;  ;  ;  ;  
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.